,This study document brings together 137 carefully worded exam questions drawn from Vermont
Pharmacist Licensure Exam with Practice Questions And Correct Answers (Verified Answers) Plus
Rationales Q&A Instant Download Pdf, with the strongest emphasis placed on Apply Vermont and
federal pharmacy laws to complex practice scenarios, including controlled substance prescribing
and collaborative practice agreements, Design and monitor evidence-based pharmacotherapeutic
regimens for acute and chronic conditions, incorporating pharmacokinetic and pharmacodynamic
principles, Evaluate sterile compounding procedures for compliance with USP <797> and <800>
standards and and perform accurate calculations for parenteral nutrition and chemotherapy. Every
item follows the wording style and level of reasoning you meet in the real paper, and each one is
paired with a clear rationale so the correct choice is never a guess. Work through the set at your
own pace, mark the questions that slow you down, then come back to them until the reasoning
feels automatic. Learners who revise this way walk into the exam room recognising the pattern
behind the questions instead of meeting them for the first time. Keep going - steady, honest
practice is what turns a difficult paper into a comfortable pass.
Q1 APPLY VERMONT AND FEDERAL PHARMACY LAWS TO COMPLEX PRACTICE
SCENARIOS, INCLUDING CONTROLLED SUBSTANCE PRESCRIBING AND COLLABORATIVE
PRACTICE AGREEMENTS
A patient with a documented severe penicillin allergy (anaphylaxis) requires
treatment for a complicated urinary tract infection caused by an
extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. Which of
the following is the most appropriate definitive therapy?
A. Meropenem CORRECT
B. Ertapenem
C. Cefepime
D. Aztreonam
RATIONALE: Meropenem is a carbapenem with stability against ESBLs and is safe in severe
penicillin allergy due to minimal cross-reactivity. Ertapenem is also a carbapenem but lacks
Pseudomonas coverage and is not preferred for ESBL infections; cefepime is a cephalosporin
with cross-reactivity risk; aztreonam is monobactam but often combined with avibactam for ESBL
and may not be optimal as monotherapy.
Page 2
,Q2 APPLY VERMONT AND FEDERAL PHARMACY LAWS TO COMPLEX PRACTICE
SCENARIOS, INCLUDING CONTROLLED SUBSTANCE PRESCRIBING AND COLLABORATIVE
PRACTICE AGREEMENTS
Which of the following best describes the legal requirement for a pharmacist to
report a suspected adverse drug reaction to the FDA under Vermont law and
federal regulations?
A. Reporting is mandatory for all adverse drug reactions under Vermont statute.
B. Reporting is voluntary for healthcare professionals, but manufacturers must report serious
events. CORRECT
C. Reporting is required only for controlled substances under the CSA.
D. Reporting is mandatory only if the reaction results in hospitalization.
RATIONALE: Under federal law (21 CFR 314.80), manufacturers must report serious adverse
events, while healthcare professionals' reporting to MedWatch is voluntary. Vermont does not
mandate pharmacist reporting of all ADRs, though some states require reporting of specific
events; controlled substances reporting is separate (PDMP).
Q3 APPLY VERMONT AND FEDERAL PHARMACY LAWS TO COMPLEX PRACTICE
SCENARIOS, INCLUDING CONTROLLED SUBSTANCE PRESCRIBING AND COLLABORATIVE
PRACTICE AGREEMENTS
A 70-kg patient is prescribed vancomycin 15 mg/kg IV every 12 hours. The
pharmacy has a 500 mg/100 mL premixed bag. How many mL should be
administered per dose? (Round to the nearest whole number.)
A. 105 mL
B. 210 mL CORRECT
C. 150 mL
D. 75 mL
RATIONALE: Dose = 15 mg/kg × 70 kg = 1050 mg. Concentration = 500 mg/100 mL = 5 mg/mL.
Volume = 1050 mg ÷ 5 mg/mL = 210 mL. Therefore, 210 mL is correct; other options reflect
calculation errors.
Page 3
, Q4 APPLY VERMONT AND FEDERAL PHARMACY LAWS TO COMPLEX PRACTICE
SCENARIOS, INCLUDING CONTROLLED SUBSTANCE PRESCRIBING AND COLLABORATIVE
PRACTICE AGREEMENTS
Which of the following is a critical violation of USP <797> for sterile compounding
that requires immediate remediation?
A. Using a horizontal laminar airflow hood for hazardous drugs. CORRECT
B. Performing hand hygiene with soap and water before donning sterile gloves.
C. Storing single-dose vials in the anteroom.
D. Cleaning the ISO Class 5 hood with 70% isopropyl alcohol before each shift.
RATIONALE: USP <797> and <800> require that hazardous drugs be prepared in a biological
safety cabinet (vertical airflow) to protect the worker; horizontal hoods are prohibited. Hand
hygiene, storage in anteroom, and cleaning with IPA are acceptable practices.
Q5 APPLY VERMONT AND FEDERAL PHARMACY LAWS TO COMPLEX PRACTICE
SCENARIOS, INCLUDING CONTROLLED SUBSTANCE PRESCRIBING AND COLLABORATIVE
PRACTICE AGREEMENTS
A patient on warfarin has an INR of 5.6 and no bleeding. Which of the following is
the most appropriate management?
A. Administer vitamin K 10 mg IV and hold warfarin.
B. Hold warfarin and administer 4-factor prothrombin complex concentrate.
C. Hold warfarin and monitor INR; consider low-dose oral vitamin K if high bleeding risk.
CORRECT
D. Continue warfarin and add aspirin 81 mg daily.
RATIONALE: For INR 5.6 without bleeding, guidelines recommend holding warfarin and
monitoring, with low-dose oral vitamin K (1-2.5 mg) considered if bleeding risk is high. IV vitamin
K is for major bleeding; PCC is for life-threatening bleeding; adding aspirin increases bleeding
risk.
Page 4
Pharmacist Licensure Exam with Practice Questions And Correct Answers (Verified Answers) Plus
Rationales Q&A Instant Download Pdf, with the strongest emphasis placed on Apply Vermont and
federal pharmacy laws to complex practice scenarios, including controlled substance prescribing
and collaborative practice agreements, Design and monitor evidence-based pharmacotherapeutic
regimens for acute and chronic conditions, incorporating pharmacokinetic and pharmacodynamic
principles, Evaluate sterile compounding procedures for compliance with USP <797> and <800>
standards and and perform accurate calculations for parenteral nutrition and chemotherapy. Every
item follows the wording style and level of reasoning you meet in the real paper, and each one is
paired with a clear rationale so the correct choice is never a guess. Work through the set at your
own pace, mark the questions that slow you down, then come back to them until the reasoning
feels automatic. Learners who revise this way walk into the exam room recognising the pattern
behind the questions instead of meeting them for the first time. Keep going - steady, honest
practice is what turns a difficult paper into a comfortable pass.
Q1 APPLY VERMONT AND FEDERAL PHARMACY LAWS TO COMPLEX PRACTICE
SCENARIOS, INCLUDING CONTROLLED SUBSTANCE PRESCRIBING AND COLLABORATIVE
PRACTICE AGREEMENTS
A patient with a documented severe penicillin allergy (anaphylaxis) requires
treatment for a complicated urinary tract infection caused by an
extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. Which of
the following is the most appropriate definitive therapy?
A. Meropenem CORRECT
B. Ertapenem
C. Cefepime
D. Aztreonam
RATIONALE: Meropenem is a carbapenem with stability against ESBLs and is safe in severe
penicillin allergy due to minimal cross-reactivity. Ertapenem is also a carbapenem but lacks
Pseudomonas coverage and is not preferred for ESBL infections; cefepime is a cephalosporin
with cross-reactivity risk; aztreonam is monobactam but often combined with avibactam for ESBL
and may not be optimal as monotherapy.
Page 2
,Q2 APPLY VERMONT AND FEDERAL PHARMACY LAWS TO COMPLEX PRACTICE
SCENARIOS, INCLUDING CONTROLLED SUBSTANCE PRESCRIBING AND COLLABORATIVE
PRACTICE AGREEMENTS
Which of the following best describes the legal requirement for a pharmacist to
report a suspected adverse drug reaction to the FDA under Vermont law and
federal regulations?
A. Reporting is mandatory for all adverse drug reactions under Vermont statute.
B. Reporting is voluntary for healthcare professionals, but manufacturers must report serious
events. CORRECT
C. Reporting is required only for controlled substances under the CSA.
D. Reporting is mandatory only if the reaction results in hospitalization.
RATIONALE: Under federal law (21 CFR 314.80), manufacturers must report serious adverse
events, while healthcare professionals' reporting to MedWatch is voluntary. Vermont does not
mandate pharmacist reporting of all ADRs, though some states require reporting of specific
events; controlled substances reporting is separate (PDMP).
Q3 APPLY VERMONT AND FEDERAL PHARMACY LAWS TO COMPLEX PRACTICE
SCENARIOS, INCLUDING CONTROLLED SUBSTANCE PRESCRIBING AND COLLABORATIVE
PRACTICE AGREEMENTS
A 70-kg patient is prescribed vancomycin 15 mg/kg IV every 12 hours. The
pharmacy has a 500 mg/100 mL premixed bag. How many mL should be
administered per dose? (Round to the nearest whole number.)
A. 105 mL
B. 210 mL CORRECT
C. 150 mL
D. 75 mL
RATIONALE: Dose = 15 mg/kg × 70 kg = 1050 mg. Concentration = 500 mg/100 mL = 5 mg/mL.
Volume = 1050 mg ÷ 5 mg/mL = 210 mL. Therefore, 210 mL is correct; other options reflect
calculation errors.
Page 3
, Q4 APPLY VERMONT AND FEDERAL PHARMACY LAWS TO COMPLEX PRACTICE
SCENARIOS, INCLUDING CONTROLLED SUBSTANCE PRESCRIBING AND COLLABORATIVE
PRACTICE AGREEMENTS
Which of the following is a critical violation of USP <797> for sterile compounding
that requires immediate remediation?
A. Using a horizontal laminar airflow hood for hazardous drugs. CORRECT
B. Performing hand hygiene with soap and water before donning sterile gloves.
C. Storing single-dose vials in the anteroom.
D. Cleaning the ISO Class 5 hood with 70% isopropyl alcohol before each shift.
RATIONALE: USP <797> and <800> require that hazardous drugs be prepared in a biological
safety cabinet (vertical airflow) to protect the worker; horizontal hoods are prohibited. Hand
hygiene, storage in anteroom, and cleaning with IPA are acceptable practices.
Q5 APPLY VERMONT AND FEDERAL PHARMACY LAWS TO COMPLEX PRACTICE
SCENARIOS, INCLUDING CONTROLLED SUBSTANCE PRESCRIBING AND COLLABORATIVE
PRACTICE AGREEMENTS
A patient on warfarin has an INR of 5.6 and no bleeding. Which of the following is
the most appropriate management?
A. Administer vitamin K 10 mg IV and hold warfarin.
B. Hold warfarin and administer 4-factor prothrombin complex concentrate.
C. Hold warfarin and monitor INR; consider low-dose oral vitamin K if high bleeding risk.
CORRECT
D. Continue warfarin and add aspirin 81 mg daily.
RATIONALE: For INR 5.6 without bleeding, guidelines recommend holding warfarin and
monitoring, with low-dose oral vitamin K (1-2.5 mg) considered if bleeding risk is high. IV vitamin
K is for major bleeding; PCC is for life-threatening bleeding; adding aspirin increases bleeding
risk.
Page 4
